Related Experiment Video

Updated: Apr 30, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.1K

Update on the molecular diagnosis and targeted therapy of thyroid cancer

Min Liu1, Maomei Ruan, Libo Chen

  • 1Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, People's Republic of China, liumin111cool@163.com.

Medical Oncology (Northwood, London, England)
|May 3, 2014
PubMed

Insights

Thyroid cancer (TC) incidence is rising. Molecular-targeted therapies offer new hope for advanced TC, improving diagnosis and treatment strategies.

Area of Science:

  • Endocrinology
  • Oncology
  • Molecular Biology

Background:

  • Thyroid cancer (TC) is the most common endocrine malignancy, with increasing incidence.
  • Current management offers good outcomes for early-stage, favorable types, but challenges remain in diagnosis and therapy.
  • Genetic alterations in TC present opportunities for novel biomarkers and therapeutic targets.

Purpose of the Study:

  • To review recent advancements in molecular diagnosis of thyroid cancer.
  • To summarize the progress in molecular-targeted therapies for thyroid cancer.
  • To highlight the potential of targeted therapies for advanced, radioiodine-refractory cases.

Main Methods:

  • Literature review of recent studies on thyroid cancer molecular diagnosis.
  • Analysis of research on molecular-targeted therapies in thyroid cancer.
  • Synthesis of findings on diagnostic and therapeutic molecular markers.

Main Results:

  • Genetic alterations are key to identifying new diagnostic and prognostic markers for TC.
  • Molecular-targeted therapies show promise, particularly for advanced and radioiodine-refractory thyroid cancers.
  • Recent progress offers improved strategies for TC management.

Conclusions:

  • Molecular insights are crucial for advancing thyroid cancer diagnosis and treatment.
  • Targeted therapies represent a significant breakthrough for challenging TC cases.
  • Continued research in molecular oncology will further refine TC patient outcomes.

More Related Videos

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.6K
Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer03:55

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer

Published on: June 9, 2023

1.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
7.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K